All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.
TRANSLATE
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View GvHD content recommended for you
ASH 2021
10 Oct 2022
In case you missed it:
At #ASH21 we examine the issues and potential solutions to the problem of differing outcomes depending on the race or ethnicity of a patient. 👉 https://t.co/6x8hEStjFY
#bmtsm #gvhd @BeTheMatch
At #ASH21 we examine the issues and potential solutions to the problem of differing outcomes depending on the race or ethnicity of a patient. 👉 https://t.co/6x8hEStjFY
#bmtsm #gvhd @BeTheMatch
20 Sept 2022
Have you seen this?
📹 #ASH21 | The GvHD hub was pleased to speak to Aleksandr Lazaryan, MD MPH PhD, @MoffittNews. We asked, How is survival impacted by belumosudil in chronic #GvHD which has failed prior therapy?
https://t.co/ltnajsZihG
📹 #ASH21 | The GvHD hub was pleased to speak to Aleksandr Lazaryan, MD MPH PhD, @MoffittNews. We asked, How is survival impacted by belumosudil in chronic #GvHD which has failed prior therapy?
https://t.co/ltnajsZihG
9 Sept 2022
📹 Catch up!
The #GvHD Hub was pleased to speak to @ckitko, @VUMChealth. We asked, Is axatilimab for cGvHD well tolerated and what does the preliminary response data look like ❓ This presentation, given by @StephanieLeeMD, was awarded Best of #ASH21 🏆
https://t.co/qHDdWNheqK
The #GvHD Hub was pleased to speak to @ckitko, @VUMChealth. We asked, Is axatilimab for cGvHD well tolerated and what does the preliminary response data look like ❓ This presentation, given by @StephanieLeeMD, was awarded Best of #ASH21 🏆
https://t.co/qHDdWNheqK
28 May 2022
🎧 Re-Listen to this #ASH21 podcast! ⏰
The #GvHD Hub was pleased to speak to steering committee member @Mohty_EBMT, Hôpital Saint-Antoine, Paris, FR. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?
https://t.co/DHMO6d5MYA
The #GvHD Hub was pleased to speak to steering committee member @Mohty_EBMT, Hôpital Saint-Antoine, Paris, FR. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?
https://t.co/DHMO6d5MYA
7 May 2022
Did you miss this from #ASH21 ❓📹
The GvHD Hub was pleased to speak to @ckitko, @VUMChealth. We asked, Is axatilimab for cGvHD well tolerated and what does the preliminary response data look like ❓ #gvhd
https://t.co/qHDdWMZD2a
The GvHD Hub was pleased to speak to @ckitko, @VUMChealth. We asked, Is axatilimab for cGvHD well tolerated and what does the preliminary response data look like ❓ #gvhd
https://t.co/qHDdWMZD2a
20 Apr 2022
🌎Did you miss our article on healthcare disparities in bone marrow transplants, from #ASH21 ❓
We examine the issues and potential solutions to the problem of differing outcomes depending on the race or ethnicity of a patient.
👉 https://t.co/6x8hESKV4y 👈
#bmtsm #gvhd
We examine the issues and potential solutions to the problem of differing outcomes depending on the race or ethnicity of a patient.
👉 https://t.co/6x8hESKV4y 👈
#bmtsm #gvhd
16 Apr 2022
🎧 Have you heard this #ASH21 podcast❓
The #GvHD Hub was pleased to speak to steering committee member @Mohty_EBMT, Hôpital Saint-Antoine. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?👀
Listen here 👇
https://t.co/DHMO6d5MYA
The #GvHD Hub was pleased to speak to steering committee member @Mohty_EBMT, Hôpital Saint-Antoine. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?👀
Listen here 👇
https://t.co/DHMO6d5MYA
12 Apr 2022
Catch up on this video from #ASH21 🎥
The GvHD Hub was pleased to speak to Guru Subramanian Guru Murthy, @MedicalCollege. We asked, how do pre-allo-HSCT conditioning regimens impact #GvHD outcomes in #myelofibrosis patients ❓
👉 https://t.co/JRXfczEeNu 👈
The GvHD Hub was pleased to speak to Guru Subramanian Guru Murthy, @MedicalCollege. We asked, how do pre-allo-HSCT conditioning regimens impact #GvHD outcomes in #myelofibrosis patients ❓
👉 https://t.co/JRXfczEeNu 👈
9 Apr 2022
Catch up on this 👀
The 14-month follow-up results of the phase II ROCKstar trial, investigating belumosudil for chronic #GvHD, have been published. Check out our updated summary from ASH21:
👉 https://t.co/rNQtnLjVa3 👈
The 14-month follow-up results of the phase II ROCKstar trial, investigating belumosudil for chronic #GvHD, have been published. Check out our updated summary from ASH21:
👉 https://t.co/rNQtnLjVa3 👈
30 Mar 2022
📚 Results from ASH21 of the standardized fecal microbiota product MaaT013 in the phase IIa Heracles trial and EAP in patients with steroid refractory GI aGvHD @Florent_Malard
👉 https://t.co/vGie6TdMkm 👈
#bmtsm #gvhdsm
👉 https://t.co/vGie6TdMkm 👈
#bmtsm #gvhdsm
15 Feb 2022
Following an informative session on healthcare disparities in bone marrow transplants at #ASH21 we examine the issues and potential solutions to the problem of differing outcomes depending on the race or ethnicity of a patient.
👉 https://t.co/6x8hESKV4y 👈
#gvhd @BeTheMatch
👉 https://t.co/6x8hESKV4y 👈
#gvhd @BeTheMatch
4 Feb 2022
📹 #ASH21 | The GvHD Hub was pleased to speak to Guru Subramanian Guru Murthy, @MedicalCollege. We asked, how do pre-allo-HSCT conditioning regimens impact #GvHD outcomes in #myelofibrosis patients ❓
https://t.co/JRXfczEeNu
https://t.co/JRXfczEeNu
19 Jan 2022
📹 #ASH21 | The GvHD hub was pleased to speak to Aleksandr Lazaryan, MD MPH PhD, @MoffittNews. We asked, How is survival impacted by belumosudil in chronic #GvHD which has failed prior therapy❓
https://t.co/ltnajsZihG
https://t.co/ltnajsZihG
12 Jan 2022
📹 #ASH21 | The #GvHD Hub was pleased to speak to @ckitko, @VUMChealth. We asked, Is axatilimab for cGvHD well tolerated and what does the preliminary response data look like ❓ This presentation, given by @StephanieLeeMD, was awarded Best of #ASH21 🏆
https://t.co/qHDdWNheqK
https://t.co/qHDdWNheqK
24 Dec 2021
⭐️#ASH21 is over but you can still find the latest updates in #GvHD from our live congress coverage in this Twitter moment!
👉Stay tuned for summary articles, expert interviews 📽️and podcasts from #ASH21!
https://t.co/YNVf75lbvD
👉Stay tuned for summary articles, expert interviews 📽️and podcasts from #ASH21!
https://t.co/YNVf75lbvD
23 Dec 2021
🎧 Listen to this #ASH21 podcast! 🎧
The #GvHD Hub was pleased to speak to steering committee member @Mohty_EBMT, Hôpital Saint-Antoine, Paris, FR. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?
https://t.co/DHMO6d5MYA
The #GvHD Hub was pleased to speak to steering committee member @Mohty_EBMT, Hôpital Saint-Antoine, Paris, FR. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?
https://t.co/DHMO6d5MYA
17 Dec 2021
Catch up on the @GvHD_hub coverage from #ASH21 here 👉 https://t.co/MYCofsxq4x to watch and read the latest in #GvHD!
Thanks for tuning in for now – look out on our social media channels for congress content coming soon in 2022.
Thanks for tuning in for now – look out on our social media channels for congress content coming soon in 2022.
14 Dec 2021
CONGRESS #ASH21 | Aleksandr Lazaryan @MoffittNews show a poster on belumosudil in chronic #GvHD: combined analysis of FFS in the KD025-208 & Rockstar Trials. The median FFS was 14 mos. The estimated overall FFS rates were 75%, 54% & 38% at 6, 12 & 24 months, respectively. #bmtsm
14 Dec 2021
CONGRESS #ASH21 | @achaudhrymedonc @SummitCancer presents a currently enrolling phase II study of BTK inhibitor MK-1026. Part 1 a dose-escalation &-confirmation phase & part 2 a cohort-expansion phase. In part 1, pts will receive MK-1026: 80, 100 or 120 mg p.o. qd. #gvhdsm #bmtsm
14 Dec 2021
CONGRESS #ASH21| Stephanie Lee @FredHutch discusses pt reported outcomes in SR-chronic #gvhd. RUX was associated with a rapid & continued reduction in mean summary mLSS, vs only an initial reduction at wk4 with BAT. Greater mean reductions were seen with RUX vs BAT at wk24 #bmtsm
14 Dec 2021
CONGRESS #ASH21 | @leventhal_r @NUFeinbergMed describes establishing dual chimerism in highly mismatched pts receiving allo-HSCT. Despite the high degree of mismatch, durable chimerism allowed for full IS withdrawal in 25/32 subjects. There have been two cases of #GvHD #bmtsm
14 Dec 2021
CONGRESS #ASH21 | Guru Subramanian Guru Murthy @Froedtert reports on flu/Bu based conditioning regimens for allo-HCT in MF. In the MAC setting, Bu/Cy was associated with a higher risk of acute #GVHD (grade 2-4 p<0.01; grade 3-4, p<0.01) & inferior GRFS (p<0.01) vs Flu/Bu. #bmtsm
13 Dec 2021
CONGRESS #ASH21 | Nathalie Dedin @HopSaintLouis @APHP talks about MAC vs non MAC + matched related HSCT. The 2-yr OS & EFS =95% in the MAC grp & 100% in the NMA grp. Incidence of gr II-IV aGVHD, NMA= 0% vs MAX= 20% (p=0.12). Incidence of cGVHD NMA 0% vs MAC 25% (p=0.06) #bmtsm
13 Dec 2021
CONGRESS #ASH21| Guru Subramian Guru Murthy @Froedtert discusses ABO incompatibility & survival post allo-HCT. Major ABO mismatch sig affected OS, platelet engraftment & primary graft failure. Sig interaction between ABO status & graft type in #aGVHD gr2-4 model was seen #bmtsm
13 Dec 2021
CONGRESS #ASH21 | @Areejmd @MassGeneralNews spoke about supportive care (SC) & was asked about improving access to SC for cGvHD. She replies that this is a big problem & to overcome it we need to develop an evidence base to support the integration of these SC measures #bmtsm
13 Dec 2021
CONGRESS #ASH21 | Chair @hamiltkyb @ClevelandClinic summarised her talk on cGvHD & was asked about systemic therapy in isolated ocular cGvHD. BH: Ocular cGvHD responds better to topical or local treatment although there may be a small a role for systemic treatment #gvhdsm #bmtsm
13 Dec 2021
CONGRESS #ASH21 | @dr_wei_jiang @WestmeadInst describes the use of 3rd party virus specific T cells + antiviral therapy in pts post-allo-HCT. Viral ORR =100% & a CR rate =94%. Of the CR pts, 22 remained virus PCR negative/ below the limit of quantitation during FU #gvhdsm #bmtsm
13 Dec 2021
CONGRESS #ASH21| Yuta Hasegawa @HokkaidoUni discusses TGF-β-dependent targeting of biliary epithelial stem cells in #gvhd. Giving a TGF-β inhibitor D+14-D+28 post allo-HCT significantly increased organoid-forming BEC stem cells, suppressed BEC apoptosis & reduced jaundice #bmtsm
13 Dec 2021
CONGRESS #ASH21 | Lu Cui @StanfordPath describes targeting of immune modulatory proteins to reduce fibrosis in sclerodermatous #gvhd. AntiCD47 + IL6 blockade was effective as a treatment for fibrosis and inflammation. They identify a novel genetic signature to target #bmtsm
12 Dec 2021
CONGRESS #ASH21| Sascha Göttert @TU_Muenchen investigates intestinal stem cell IFNγ mediated damage by donor T cells. Recipient mice with increasingly dense GI infiltration by allo-T cells develop more severe #GVHD & show increased recovery potential early after allo-SCT #bmtsm
12 Dec 2021
CONGRESS #ASH21| Viktor Arnhold @sloan_kettering describes the effect of corticosteroid use on GI #gvhd. CS treatment can suppress epithelial proliferation & exacerbate GI damage. However, these effects can be counterbalanced by promotion of epithelial regeneration #bmtsm
12 Dec 2021
CONGRESS #ASH21| @matrixat @TU_Muenchen on microbial metabolite recovery: microbial metabolites detected in pts can engage the STING pathway & allow to resist immune damage. Prophylactic administration of bacteria that can produce these metabolites may reduce #GVHD in SCT #bmtsm
12 Dec 2021
CONGRESS #ASH21| Shuichiro Takashima @sloan_kettering is speaking about intestinal stem cells & crypt regen in #gvhd. Epithelial STAT1 contributes to crypt regeneration in GVHD by transmitting T-cell-derived JAK/STAT cytokine signalling to activate Myc expression in ISCs. #bmtsm
12 Dec 2021
CONGRESS #ASH21| Eiko Hayase @MDAndersonNews discusses carbapenem antibiotics in a mouse model of #gvhd. Meropenem treatment aggravated GvHD in the colon & reduced the mucus layer. Meropenem-treated mice given xylose show reduced GvHD severity & improved survival #bmtsm
12 Dec 2021
CONGRESS #ASH21| Mesire Aydin @amsterdamumc presents a review of HSCT outcomes in patients with sickle cell disease. The results of haplo-SCT showed relatively low overall pooled proportions of graft failure (7%), acute (4%) & chronic (11%) GvHD. OS was high (91%) #gvhdsm #bmtsm
12 Dec 2021
CONGRESS #ASH21| Amin Turki @WPE_Essen presents the validation of a machine learning derived grading system for acute #gvhd. Four grades with 12 stages were described. The 12-month OS probability was 75.3% for ML-I, 61.5% for ML-II, 31% for ML-III and 9.1% for ML-IV #bmtsm
11 Dec 2021
CONGRESS #ASH21| Karamjeet Sandhu @cityofhope talks about clostridium butyricum MIYAIRI 588 (CBM588) a live biotherapeutic product that produces SCFAs & is used in HCT recipients. Only 1 SAE on CBM588. 100-day NRM =0%, Treatment & 6.7% in the Control arm. #gvhdsm #bmtsm
11 Dec 2021
CONGRESS #ASH21| @matrixat @TU_Muenchen describes a multicentre study combining bacteriome, mycobiome, virome & metabolome analyses in a longitudinal fashion in matched pt cohorts. ASCT pts show sig loss of diversity & ability of microbiome to produce metabolites #gvhdsm #bmtsm
11 Dec 2021
CONGRESS #ASH21| Hana Andrlova @sloan_kettering discusses findings showing that a diverse microbiota supports the reconstitution of protective unconventional T cell populations, e.g., MAIT & Vδ2 cells, which are associated with a favourable HCT outcome. #gvhdsm #bmtsm
11 Dec 2021
📍#ASH21| Abatacept is active in steroid-refractory chronic GvHD, as reported by Anita Koshy @harvardmed. This ph I reports responses in patients with a median of 5 prior lines, leading to durable reductions of prednisone dose #gvhdsm #bmtsm
11 Dec 2021
📍#ASH21 | @StephanieLeeMD presents the data from axatilimab, an anti-CSF-1R mAb, in cGvHD. 43% of patients are still on treatment, but so far, 53% of them showed clinically meaningful improvements in symptoms, with a 68% response rate and no viral react @fredhutch #gvhdsm #bmtsm
11 Dec 2021
📍 #ASH21 | @Florent_Malard shared the data of MaaT 013 in steroid resistant/dependent aGvHD from the HERCULES ph II trial and a EAP and showed to be safe in highly immunosuppressed patients. @Sorbonne_Univ_ @APHP #gvhdsm #bmtsm
11 Dec 2021
11 Dec 2021
CONGRESS #ASH21| Ke Zhao @smu_medical presents a phase 3 trial of MSCs + antiCD25 AB for SR #gvhd in 203 pts. OR at day 28 was higher in the MSCs vs control groups (82% vs 70% P=.043). The 2-year CI of cGVHD was 39.5% & 62.7% in the MSCs & control groups (P=0.005). #bmtsm
11 Dec 2021
CONGRESS #ASH21 | @albertomussetti @Hhospitalet compares haplo-HCT and MUD HCT when PTCy is used as prophylaxis in 2155 lymphoma patients. OS was 72% at 1 year & 63% at 2 years. Relapse was 22% at 1 year & 27% at 2 years. All outcomes favoured MUD over haplo #gvhdsm #bmtsm
11 Dec 2021
CONGRESS #ASH21 | Swati Naik @StJudeResearch describes using CD54RA+ cell depletion in haplo-SCT to limit #gvhd in a clinical trial of 72 pts. The cumulative incidence of aGVHD was 36%, aGVHD grade III-IV was 29% & cGVHD was 24%. The 3-year OS & LFS was 69% & 62% #bmtsm #gvhdsm
11 Dec 2021
CONGRESS #ASH21| Joseph Oved @sloan_kettering is speaking about ex vivo TCR αβ+/CD19+depletion of mobilized PSC from MUD & MMUD for pediatric patients (N=29) with BMF. At a median FU of 713 days (42-1581), 28/29 patients are alive with resolved hematologic disease #gvhdsm #bmtsm
11 Dec 2021
CONGRESS #ASH21| @GabyHobbs @MassGeneralNews presents the interim results of a phase II study of rux pre &post SCT for pts (n=26) with MF. Median FU of 12 mo, 1-yr GRFS was 65%. OS, PFS, & cumulative incidence of NRM & relapse were 77%, 71%, 13% & 17%, respectively #gvhdsm #bmtsm
11 Dec 2021
CONGRESS #ASH21| @pietro_merli @bambinogesu talks about children (N=23) with MDS receiving an αβT and B-cell depl-haploHSCT from an HLA-partially matched relative. 5-year probability of OS & EFS were 92.3% & 76.2%, respectively. 5-yr disease-free-survival was 88.6% #gvhdsm #bmtsm
11 Dec 2021
CONGRESS #ASH21| Maryan Ali @Oslounivsykehus shows the results for a RCT of extracorporeal photopheresis in preventing #gvhd. (N=157) No significant difference in the numbers, types, organ involvement or severity of GvHD between the intervention & the control group #bmtsm
11 Dec 2021
CONGRESS #ASH21| @ramziabb @WUDeptMedicine @WashUHeme speaks about the results of itacitinib for #GvHD prophylaxis. Itacitinib+PB haplo-HCT was safe with no engraftment failure & prompt engraftment. Rates of acute & cGVHD were low, without increased risk of relapse or TRM #bmtsm
11 Dec 2021
CONGRESS #ASH21| @hamiltkyb @ClevelandClinic compares Full-MTX to a reduced dose-MTX regimen + MMF & found no difference in acute or cGVHD incidence & a more favourable toxicity profile, with faster engraftment, less mucositis, less organ toxicity, & lower NRM #gvhdsm #bmtsm
11 Dec 2021
CONGRESS #ASH21| Everett Meyer @StanfordPath presents the results from a single centre phase I/II & a multicentre phase Ib trial of Orca-T, an investigational engineered donor graft therapy. Both studies, GRFS =74% vs 34% SOC & OS =90% vs 78% SOC at 1 yr was achieved #gvhd #bmtsm
11 Dec 2021
CONGRESS #ASH21| Pietro Crivello @UniklinikEssen shows that single HLA class I peptide binding motifs (PBM)-mismatches are significantly associated with worse survival after 9/10 HLA-MUD-HCT compared to PBM-matched or unidirectional mismatching in the HvG direction #gvhdsm #bmtsm
10 Dec 2021
CONGRESS #ASH21| Muna Qayed @EmoryUniversity presents innovative strategies for the prevention of #gvhd including abatacept, ATG & PTCy alone or in combinations. She also discusses newer agents e.g., JAKis, vedolizumab & sitagliptin which are undergoing phase I/II testing #bmtsm
10 Dec 2021
CONGRESS #ASH21| Nicolaus Kroeger @UKEHamburg focuses on alternative donors in BMT. He states that retrospective and prospective studies currently favour haploidentical with PTCy to cord blood and mismatched unrelated donors #bmtsm
10 Dec 2021
CONGRESS #ASH21| Steven Devine @BeTheMatch discusses the role of the national marrow donor program. He highlights that the odds of finding a match based on ethnic background is only 29% in black or African American communities compared with 79% for white patients #bmtsm
7 Dec 2021
📢 With #ASH21 right around the corner, check out our what's hot in #GvHD list for the top abstracts to look out for!
https://t.co/1up4BuGnrF
https://t.co/1up4BuGnrF
12 Nov 2021
RT @ASH_hematology: Our featured hashtags can help you with #ASH21-specific posts, but we have also compiled a list of hashtags to help you…
11 Nov 2021
RT @ASH_hematology: Make the most of your #ASH21 experience whether you're joining virtually or heading to Atlanta! 💻✈️ This year's feature…
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content